Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening

Parallel screening comprises a novel in silico method to predict the potential biological activities of a compound by screening it with a multitude of pharmacophore models. Our aim is to provide a fast, large-scale system that allows for virtual activity profiling. In this proof of principle study, carried out with the software tools LigandScout and Catalyst, we present a model work for the application of parallel pharmacophore-based virtual screening on a set of 50 structure-based pharmacophore models built for various viral targets and 100 antiviral compounds. The latter were screened against all pharmacophore models in order to determine if their biological targets could be correctly predicted via an enrichment of corresponding pharmacophores matching these ligands. The results demonstrate that the desired enrichment, that is, successful virtual activity profiling, was achieved for approximately 90% of all input molecules. We discuss descriptors for output validation, as well as various aspects influencing the analysis of the obtained activity profiles, and the effect of the utilized search modus for screening.

[1]  T Langer,et al.  Lead optimization Pharmacophore definition and 3 D searches , 2005 .

[2]  L. Stolk,et al.  Increasing number of anti-HIV drugs but no definite cure Review of anti-HIV drugs , 2004, Pharmacy World and Science.

[3]  Osman Güner,et al.  Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. , 2004, Current medicinal chemistry.

[4]  Erik De Clercq,et al.  Antiviral drugs in current clinical use. , 2004 .

[5]  E. Clercq,et al.  Highlights in the development of new antiviral agents. , 2002 .

[6]  Jan Balzarini,et al.  Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. , 2005, Journal of medicinal chemistry.

[7]  M G Rossmann,et al.  Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Lars Bohlin,et al.  Rediscovery of known natural compounds: nuisance or goldmine? , 2005, Bioorganic & medicinal chemistry.

[9]  Thierry Langer,et al.  Comparative Analysis of Protein‐Bound Ligand Conformations with Respect to Catalyst′s Conformational Space Subsampling Algorithms. , 2005 .

[10]  Q. Do,et al.  Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin , 2005 .

[11]  E. Arnold,et al.  Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. , 1996, Journal of molecular biology.

[12]  Alexander Tropsha,et al.  Chemometric Analysis of Ligand Receptor Complementarity: Identifying Complementary Ligands Based on Receptor Information (CoLiBRI) , 2006, J. Chem. Inf. Model..

[13]  A. Tomasselli,et al.  Targeting the HIV-protease in AIDS therapy: a current clinical perspective. , 2000, Biochimica et biophysica acta.

[14]  J. Balzarini,et al.  Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. , 2004, Current topics in medicinal chemistry.

[15]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[16]  Thierry Langer,et al.  The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling. , 2005 .

[17]  Jie Zhang,et al.  Recent advances in anti-influenza agents with neuraminidase as target. , 2006, Mini reviews in medicinal chemistry.

[18]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[19]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[20]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[21]  T. Klabunde,et al.  GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.

[22]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[23]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[24]  G. Taylor,et al.  Neuraminidase inhibitors as antiviral agents. , 2005, Current drug targets. Infectious disorders.

[25]  U Norinder,et al.  In silico modelling of ADMET—a minireview of work from 2000 to 2004 , 2005, SAR and QSAR in environmental research.

[26]  P. Lam,et al.  DE NOVO DESIGN, DISCOVERY AND DEVELOPMENT OF CYCLIC UREA HIV PROTEASE INHIBITORS , 1998 .

[27]  Torsten Herbertz,et al.  Allosteric Inhibitors of Hepatitis C NS5B RNA-dependent RNA Polymerase° , 2005 .

[28]  Osman F Guner.  The impact of pharmacophore modeling in drug design. , 2005, IDrugs : the investigational drugs journal.

[29]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[30]  M S Chapman,et al.  Human rhinovirus 14 complexed with antiviral compound R 61837. , 1991, Journal of molecular biology.

[31]  Osman F. Güner,et al.  Use of Pharmacophores in Predictive ADME , 2007 .

[32]  Uwe Koch,et al.  Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site* , 2005, Journal of Biological Chemistry.

[33]  Pooran Chand,et al.  Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. , 2005, Bioorganic & medicinal chemistry.

[34]  Meitian Wang,et al.  Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.

[35]  Jeffrey A Pfefferkorn,et al.  Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.

[36]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  E. De Clercq,et al.  The HIV‐1 Reverse Transcription (RT) Process as Target for RT Inhibitors , 2000, Medicinal research reviews.